Trial reportFrontiers in cardiovascular medicine2026
Electroacupuncture for slow flow/no-reflow in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a pilot randomized controlled trial.
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Slow flow/no-reflow (SF-NR) complicates up to 44% of percutaneous coronary interventions (PCI) for acute myocardial infarction (AMI), worsening prognosis. Electroacupuncture (EA) may mitigate SF-NR, but clinical evidence is limited. Objective: This trial was designed to assess the feasibility and effectiveness of intraoperative EA in reducing SF-NR during PCI for AMI patients. Design setting and participants and interventions: This single-center, randomized, assessor-blinded pilot trial enrolled 60 eligible AMI patients undergoing PCI at Yueyang Hospital, China, from August 2023 to March 2024. Participants were randomized to receive PCI with electroacupuncture (EA) stimulating Neiguan (PC6) and Ximen (PC4) acupoints, or PCI alone (control group). Main outcomes and measures: The primary outcome was the incidence of SF-NR. Secondary outcomes included chest pain (Numerical Rating Scale, NRS), anxiety (Visual Analog Scale for Anxiety, VAS-A), and the occurrence of major adverse cardiac and cerebrovascular events (MACCE) within 30 days, cardiac biomarkers, inflammatory markers. Results: All 60 patients completed the trial (mean [SD] age, 63.2 [11.4] years; 86.7% male [52/60]). EA significantly reduced SF-NR incidence compared with control (6.7% [2/30] vs. 26.7% [8/30]; RR, 0.2; 95% CI, 0.0 to 0.4; Conclusions: Intraoperative EA during PCI was associated with reduced SF-NR and attenuated early inflammation. Improvements in patient-reported pain and anxiety were also observed, though the influence of non-specific effects cannot be ruled out. These preliminary findings demonstrate the feasibility of EA as a PCI adjunct and indicate a potential signal for efficacy, larger multicenter, sham-controlled trials larger multicenter, sham-controlled trials are needed. Clinical Trial Registration: https://www.chictr.org.cn/, ChiCTR2300072265.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.